Aerie Pharmaceuticals Logo

We are committed to building a major ophthalmic pharmaceutical company. Our pathway to global leadership in eye care is based on continuous scientific innovation, world-class clinical development, and company-wide operational excellence in the pursuit of novel treatments for diseases of the eye with significant unmet need.

Learn More About Our Mission:

Aerie Corporate Highlights

  • Aerie Pharmaceuticals, Inc. is a publicly-traded company (NASDAQ: AERI)
  • Offices
    • HQ – Durham, NC
    • Irvine, CA
    • Bedminster, NJ
    • Dublin, Ireland
    • Tokyo, Japan
    • Henley-on-Thames, United Kingdom
  • Manufacturing Facilities
    • Athlone, Ireland (cGMP sterile fill plant)
    • Durham, NC (cGMP PRINT® implant production laboratory)
  • Employees: Approximately 400

Aerie Product Portfolio

  • Rhopressa® (netarsudil ophthalmic solution) 0.02%
    • U.S. FDA approval – December 2017
    • U.S. commercial launch – April 2018
  • Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
    • U.S. FDA approval – March 2019
    • U.S. commercial launch – May 2019
  • Rhokiinsa® (netarsudil 200 micrograms/ml eye drops solution)
    • EU marketing authorisation – November 2019
  • Roclanda® (netarsudil 200 micrograms/ml and latanoprost 50 micrograms/ml eye drops)
    • EU marketing authorisation – January 2021
    • Mercury 3 90-day topline results announced
    • Marketing authorisation for Great Britain – April 2021

Pipeline Activities

  • Globalization plan for netarsudil franchise under way
    • Europe
      • Commercialization planning underway
    • Japan
      • Phase 2 study of netarsudil completed
      • Exclusive collaboration and license agreement completed with Santen for Japan and 8 other Asian nations.
      • First Phase 3 trial enrollment completed; topline results Q4 2021
  • Dry Eye Disease program
    • AR-15512 (TRPM8 receptor agonist eye drop)
      • Phase 2b trial (COMET-1) enrollment completed; topline results Q3 2021
  • Retinal Disease program
    • AR-1105 (dexamethasone sustained release implant)
      • Positive Phase 2 topline results reported July 2020
      • Phase 3 planning underway in the U.S. and EU
    • AR-13503 (Rho kinase/Protein kinase C inhibitor sustained release implant)
      • First-in-human clinical study ongoing
    • AR-14034 (Pan-VEGF receptor inhibitor sustained release implant)
      • IND-enabling pre-clinical studies underway
  • Ocular Inflammation program
    • AR-6121 (Rho kinase inhibitor-linked-steroid – “ROCK’Ster”)
      • IND-enabling pre-clinical studies underway
  • Small-molecule multi-kinase inhibitors in discovery and pre-clinical development for other ophthalmic diseases and conditions
    • Proprietary library of more than 4,000 molecules
TOP